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Abstract
Background: Annual mass drug administration (MDA) using diethylcarbamizine (DEC, 6 mg/kg)
combined with albendazole (alb, 400 mg) is recommended by the Global Programme to Eliminate
Lymphatic Filariasis (GPELF). This strategy has been shown to be efficient in the of control
bancroftian filariasis, but data on brugian filariasis as well as on the positive side effects on intestinal
helminths are lacking.
Methods: The effect of one selective treatment and two rounds of MDA using DEC and alb on
the prevalence and intensity of Brugia timori infection were studied on Alor island using a cross-
sectional and a cohort approach. Before the campaign and ten months after each treatment cycle
microfilariae (mf) were assessed by filtration of night blood. Before and ten months after MDA,
stool samples were collected and the prevalence of intestinal helminths were determined.
Results: In all, the mf-rate dropped from 26.8% before any treatment to 3.8% following the second
MDA. Almost all mf-positive, treated individuals showed very low mf densities. The crude
prevalence of hookworm dropped from 25.3% to 5.9%. The reduction of prevalence of Ascaris
lumbricoides (32.3% to 27.6%) and Trichuris trichiura (9.4% to 8.9%) was less pronounced. Within a
cohort of 226 individuals, which was examined annually, the prevalence of A. lumbricoides dropped
from 43.8% to 26.5% and of T. trichiura from 12.8% to 6.6%. The results indicate that this MDA
approach reduces not only the mf prevalence of B. timori but also the prevalence of hookworm and
to a lesser extent also of A. lumbricoides and T. trichiura.
Conclusion: The MDA using DEC and alb as recommended by GPELF is extremely effective for
areas with brugian filariasis. The beneficial effect of MDA on intestinal helminths may strengthen
the national programme to eliminate lymphatic filariasis in Indonesia and may set resources free
which are otherwise used for deworming campaigns of schoolchildren.
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Background
Lymphatic filariasis (LF) has been targeted by the World
Health Organization for elimination as a public health
problem by the year 2020 [1,2]. It is caused by three spe-
cies of filarial parasites: Wuchereria bancrofti infects about
115 million people in Africa, India and other tropical and
subtropical areas, whereas Brugia malayi infects about 13
million people in south India and south-east Asia and it is
replaced by its sibling species Brugia timori in eastern
Indonesia and Timor-Leste [3]. In Asia, the key strategy of
the Global Programme to Eliminate LF (GPELF) is an
annual mass drug adminstration (MDA) of all individuals
at risk of infection with a single annual dose of diethylcar-
bamazine (DEC) combined with albendazole (alb) for at
least four to five subsequent years [2,4]. This approach has
been shown to reduce microfilaraemia of W. bancrofti and
B. malayi efficiently [5-7]. Studies in areas endemic for W.
bancrofti also indicate that the treatment with DEC com-
bined with alb has the additional long-term beneficial
effect of reducing prevalence and intensity of infection
with intestinal helminths such as Ascaris lumbricoides,
hookworms and Trichuris trichiura [8-11].
In 2001, The Department of Health of the Indonesian
Government decided to participate in the GPELF.
Although Indonesia has a long history in filariasis control
programmes [12], filariasis is still in many areas a large
public health problem and the new strategy recom-
mended by GPELF was never evaluated. Therefore, studies
were initiated to investigate the efficacy of a single dose
DEC combined with alb to control W. bancrofti and B.
timori infections on Alor island [13]. The treatment was
judged to be efficient and safe enough to be employed in
an MDA approach and an area endemic for B. timori was
selected for annual follow-up studies [13-15].
In the present study we examined the prevalence of B.
timori microfilaraemia following one selective treatment
and two annual rounds of MDA using DEC combined
with alb in a highland village of Alor island. We assessed
the prevalence of intestinal helminths before MDA and its
impact on the prevalence of the most common intestinal
helminths, A. lumbricoides, hookworms and T. trichiura.
We provide data on the effectiveness of two annual single
doses of DEC and alb treatment to control B. timori and
intestinal helminths.
Methods
Study area
The study was performed in Mainang village on Alor
island (East Nusa Tenggara Timor, Indonesia). This village
was first characterized in April 2001, and it was found to
have a prevalence of B. timori microfilaraemia of about
25%. [16]. About 40% of the inhabitants showed signs of
infection and 80% presented IgG4 antibodies reactive
with a recombinant B. malayi antigen, BmR1 [16,17].
Anopheles barbirostris mosquitoes were identified as vectors
for B. timori [18]. An animal reservoir for this Brugia spe-
cies is not known and wild-life as well as domestic ani-
mals were rare in the study village. Before treatment
intestinal helminths were common, especially A. lumbri-
coides (prevalence 2002, 32.3%) and hookworms (preva-
lence 2002, 25.3%) as well as T. trichuria (prevalence
2002, 9.4%). In the study area a few individuals received
diethylcarbamazine (DEC) before 1990 and no
anthelminthics were commercially available on the
island. However, a deworming campaign was performed
in schoolchildren at irregular intervals using generic ben-
zimidazole derivates before the year 2000. In the village
about 60% of eligible children attended school.
Sample collection
Originally, the study was planned as a cohort-study with
annual re-examinations. Since the most appropriate travel
period to Alor is also harvesting season, many farmers
were absent from their home during the re-examinations.
Therefore, in 2001, 2002, 2003 and 2004 between 37 and
51% of the total resident population (about 1,500 indi-
viduals) were examined and data were analysed using a
cross-sectional approach. The percentage of newly regis-
tered individuals, decreased from 45% during the first
annual re-examination in 2002 to 25% in 2003 and to
20% in 2004. By summarizing all surveys, about 90% of
the resident population living in the area in 2001
attended at least one survey. Only 145 (10%, 70 males, 75
females, median age in the year 2001, 26 years) individu-
als participated in all four filariasis surveys and 226 (15%,
117 males, 109 females, median age in the year 2002, 22
years) in the three surveys which included stool collec-
tion. Data of these individuals were also analysed sepa-
rately as a cohort.
In May 2001 about 200 selected individuals with micro-
filariae (mf) and/or lymphoedema received a single dose
of DEC (6 mg/kg) combined with alb (400 mg) [13]. This
number represented about 40% of the total number of
individuals with mf and/or lymphoedema in the study
area. A second survey was performed in April/May 2002 to
assess the long-term efficacy of the filariasis treatment in
selected individuals. The treatment results of these mf-
positive individuals were reported previously [13,14]. For
comparison their data were also included in this report. In
addition, during the 2002 survey, baseline data on the
prevalence of intestinal helminths were collected. Re-
examination following MDA was carried out from April to
May 2003 and from March to April 2004. Inhabitants of
the endemic villages were called by their local health
workers to a central place, usually the Puskesmas (primary
health center). For each volunteer, sex, age and name were
noted and after a brief clinical examination venous bloodFilaria Journal 2005, 4:5 http://www.filariajournal.com/content/4/1/5
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was collected between 7.00 p.m. and 11 p.m. One labeled
stool container was provided to each individual partici-
pating in the study and collected one day later by local
health workers.
The participants came from three different residential
quarters of Mainang, Welai Selatan, Malaipea and
Tominuku, but no significant differences with regard to
the prevalence of B. timori or intestinal helminths were
found [16]. All individuals over the age of two years were
asked to participate in the study. Informed consent was
obtained from all adults or, in the case of children, from
their parents. The study was approved by the ethical board
of the University of Indonesia, Jakarta. Following the reg-
istration, the individuals were examined by experienced
physicians for clinical signs of lymphatic filariasis. During
the survey patients with lymphoedma were introduced to
hygiene of affected legs and other procedures which may
help to stop the progression or alleviate symptoms of their
disease.
Mass drug administration
In May and June 2002 and 2003, after each survey, a com-
munity based MDA using a single dose of DEC and alb for
the entire eligible population was performed. Pregnant or
breastfeeding women, children younger than two years or
persons suffering from acute illness were not treated. A
medication regimen based on the classification of age
rather than on weight was used (Table 1), since this was
found to facilitate treatment.
The MDA of the rest of the island was conducted by the
District Health Authority, which claims a coverage rate
(number of distributed doses per number of residents) of
78%. Staff from the GTZ performed MDA in 6 randomly
selected  B. timori and/or  W. bancrofti endemic villages
with a total population of about 6,000 inhabitants and
introduced a developed educational programme [19]. For
MDA a mixed approach was used, involving both, the pri-
mary health care system and the community members
directly. Health staff and volunteers were trained for cor-
rect drug distribution and documentation as well as side
effect recognition and its treatment. The impact of this
campaign was tested by using KAP (knowledge, attitudes,
practice) surveys before and after the intervention [19]. In
this project a MDA coverage rate of 75% was achieved,
whereas 15% of the population, according to WHO guide-
lines, were not eligible for treatment. Besides the effect of
treatment the educational programme has increased the
knowledge about filariasis. In our study village Mainang
in April 2003 a compliance rate (number of persons who
reported to have taken the drug per number of residents)
for the 2002 MDA of 67% was determined (n = 772).
Assessment of microfilariae
For the identification of mf-positive individuals, 1 ml of
anticoagulated blood (EDTA) was filtered through a poly-
carbonate membrane with a 5 µm pore size (Millipore,
Eschborn, Germany). Subsequently mineral water was
passed through the membrane for blood cell lysis. The
membrane was placed on a slide, air-dried and fixed with
methanol. Following Giemsa staining, slides were air-
dried, examined microscopically using 100-fold magnifi-
cation and mf were counted.
Assessment of helminth eggs
In the field, the Harada-Mori hatching test was used to
detect living hookworm larvae. Briefly about 0.5 g fresh
stool was spread on a wet filter paper and placed with 1
ml water in a specially designed plastic bag. The bags were
placed upright in a window, covered by paper and incu-
bated for 6 to 10 days. The samples were examined micro-
scopically for the presence of hookworm larvae at a 63-
fold magnification. The rest of the stool samples were pre-
served in the field using 4% formaldehyde. In the labora-
tory in Jakarta, 1–2 g of stool was examined by the
formalin/ether enrichment method for the presence of
helminth eggs. The most prevalent geohelminths, A. lum-
bricoides, hookworm and T. trichiura were analysed in this
study, since other species such as Hymenolepis spp. and
Strongyloides stercoralis were only found in a few cases.
In the baseline survey in 2002 the Kato-Katz smear was
used to assess the helminth eggs quantitatively. Com-
pared to the enrichment method and the Harada-Mori test
the Kato Katz technique had a poor sensitivity and this
method was not applied in the following years. In 2002
the number of eggs per gram (epg) in infected individuals
as determined by the Kato Katz smear was usually rela-
tively low with medians for A. lumbricoides, hookworms
Table 1: Simplified dosing regimen used for mass drug administration of DEC (100 mg tablets) and albendazole (400 mg tablets) to 
control lymphatic filariasis on Alor island, Indonesia, compared to the average body weight (2002, standard deviation, SD).
Age DEC Albendazole Mean body weight in kg (SD)
2–6 years, pre-school 1 tablet 1 tablet 14.4 (6.4)
7–12 years, primary school 2 tablets 1 tablet 23.6 (5.2)
13 years and older, high school and adults 3 tablets 1 tablet 45.7 (9.1)Filaria Journal 2005, 4:5 http://www.filariajournal.com/content/4/1/5
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and T. trichiura of 3,500 epg, 50 epg and 75 epg, respec-
tively. For the enrichment method and the Harada Mori
test, the numbers of helminth eggs or hookworm larvae
were scored as follows: low density (1–10 eggs per slide or
1–50 hookworm larvae per plastic bag), moderate density
(11–100 eggs or 51–500 larvae) or high density (more
than 100 eggs or 500 larvae). Usually, scoring data are in
good agreement with results obtained by the Kato Katz
Smear [20].
Statistical analysis
EpiInfo 2002 Revision2 was used for documentation and
analysis of the data. As index for the mf density within a
study group the geometric mean was used. For the estima-
tion of the community mf load (CMFL) a log (x+1) trans-
formation was used. Data on distribution and density of
mf were compared using the chi-square test or the Mann-
Whitney U test.
Results
Brugia timori
In the years 2001 to 2004 a total of 586, 769, 768, and
704 individuals, respectively, were examined for the pres-
ence of mf (Table 2, Fig. 1). In 2001, a B. timori mf preva-
lence of 26.8% was observed, which dropped one year
after selective treatment in 2002 to 17.6 %. In 2003, about
one year following the first round of MDA, a mf preva-
lence of 6.1% was detected, while in 2004, about one year
following the second round of MDA, a mf prevalence of
3.8% was recorded (Fig. 1A). There was no difference in
prevalence reduction between male and female individu-
als (P > 0.05). In total, from 2001 to 2004 a reduction of
mf prevalence of 85% was observed.
The CMFL, the geometric mean number of mf per exam-
ined person including the mf-negative individuals,
dropped from 3.8 mf/ml in 2001 to 1.1 mf/ml in 2004
(Fig. 1B). However, due to the used definition of the
CMFL its minimum is 1 mf/ml and in areas with low prev-
alence and low mf densities the CMFL becomes inaccu-
rate. While in 2001, 31.2% of 157 mf-positive individuals
had high mf densities of more than 500 mf/ml, this per-
centage decreased in 2002 to 12.2% of 135, in 2003 to
17.0% of 47 and in 2004 to 11.1% of 27 microfilaraemics
(Table 2).
The mf-positive individuals, who received their first treat-
ment in 2001, were re-examined after six, twelve, 24 and
34 months. In 2004, 73 of these individuals could be re-
examined. Most of them had received three treatments
and the prevalence dropped from 100% to 5.5%. The geo-
metric mean mf density of the mf-positive individuals
dropped from 142 mf/ml before treatment (2001) to 1.1
mf/ml after 34 months (2004).
In order to determine the dynamics of the mf-status dur-
ing the investigation period, the mf prevalence in a cohort
of 145 individuals, who participated in all four annual
surveys, was determined (Fig. 2). In this group 42 (29.0%)
individuals, with a geometric mean mf density of 148.6
mf/ml, were mf-positive in 2001. In 2002, 7 formerly mf-
negative individuals became microfilaraemic, while 30
formerly mf-positive individuals became amicrofilarae-
mic after the selective DEC and alb treatment. In 2003,
following the first round of MDA, no new microfilarae-
mics were observed, while 5 individuals remained mf-
positive. Three of these individuals had very low mf den-
sities. Two individuals claimed not to have participated in
MDA a year before. In both individuals the mf density
increased from 2002 to 2003 from 5 to 27 mf/ml and
from 726 to 2,723 mf/ml, respectively. In 2004, following
the second round of MDA two individuals became micro-
filaraemic who were mf-negative the year before and one
person remained microfilaraemic. The mf density for the
3 mf-positives, who were all positive at the beginning of
the observation period, was 1.3 mf/ml, which is a
reduction from 2001 to 2004 of >99% for the mf-positives
(Fig. 2).
Table 2: Number of individuals examined for B. timori from 2001 to 2004 grouped by mf density and the numbers of individuals who 
claimed to have been treated with DEC/albendazole in the previous year.
Mf/ml 2001 No. (%) 2002 No. (%) 2003 No. (%) 2004 No. (%)
Examined* Treated** Examined* Treated** Examined* Treated** Examined* Treated**
0 429 (73.2) 0 634 (82.4) 126 (19.9) 721 (93.9) 482 (66.9) 677 (96.2) 548 (80.9)
1–100 66 (11.3) 0 90 (11.7) 22 (24.4) 25 (3.3) 17 (68.0) 20 (2.8) 14 (70.0)
101–500 42 (7.2) 0 29 (3.8) 6 (20.7) 14 (1.8) 6 (42.9) 4 (0.6) 2 (50.0)
>500 49 (8.3) 0 16 (2.1) 1 (6.3) 8 (1.0) 4 (50.0) 3 (0.4) 0 (0)
Total 586 (100) 0 769 (100) 155 (20.5) 768 (100) 509 (66.3) 704 (100) 564 (80.1)
*percentage of total examined, **percentage of negative or positive examinedFilaria Journal 2005, 4:5 http://www.filariajournal.com/content/4/1/5
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(A) Prevalence of B. timori mf positive individuals in Mainang village, Alor, Indonesia, from 2001 to 2004 by age Figure 1
(A) Prevalence of B. timori mf positive individuals in Mainang village, Alor, Indonesia, from 2001 to 2004 by age. The number of 
individuals examined is noted on top of each column. Selective DEC/albendazole treatment was performed after the survey in 
2001. MDA was performed after the surveys in 2002 and 2003. (B) Communtiy microfilarial load (CMFL) of B. timori in Mainang 
village, Alor, Indonesia, from 2001 to 2004 by age. Due to definition the minimum of CMFL is 1 microfilaria per ml night blood 
(mf/ml).
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Ascaris lumbricoides
To asses the effects of the MDA on the prevalence of intes-
tinal helminths stool samples were collected in 2002
before MDA and in 2003 and 2004 about 10 months after
MDA. In the years 2002, 2003 and 2004 stool samples
were collected from 651, 565 and 576 individuals, respec-
tively (Table 3, Fig. 3).
The crude prevalence of A. lumbricoides dropped from
32.3% in 2002 to 22.1% in 2003. However, in 2004 a
crude prevalence of 27.6% was observed (Table 3). No dif-
ference in prevalence reduction was observed in male and
female individuals. Children under the age of ten years
had the highest infection rate of 28.7% (2002), 29.6%
(2003) and 43.7% (2004), whereas in the other age
groups no increase of prevalence was observed (Fig. 3A).
In contrast to these crude data, a significant decrease of A.
lumbricoides prevalence was observed in a cohort of 226
individuals, who were examined in 2002, 2003 and 2004
(Fig. 4A). In these three years the prevalence dropped in
this cohort from 43.8% to 28.3% and to 26.5%. This is a
reduction of 39.7% after two rounds of MDA with a com-
pliance rate of 86% and 95%. In 2003, 33 new infections
occurred, while 68 individuals who were infected with A.
lumbricoides became negative. In 2004, 38 new infections
occurred, while 41 persons turned negative (Fig. 4A). In
2003 and 2004 about 90% of the infected individuals had
light infections with an estimate of less than 2,000 eggs /
Number of people examined each year from 2001 to 2004 for B. timori and geometric mean of the mf-positives Figure 2
Number of people examined each year from 2001 to 2004 for B. timori and geometric mean of the mf-positives. The white 
boxes are mf-negative individuals, the grey boxes the mf-positive individuals. The percentages on the arrow indicate the treat-
ment compliance. In the table the boxes marked with the stars differentiate the mf density.
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g stool, whereas before treatment 50% of the examined
individuals had 3,500 eggs /g or more.
Hookworms
The crude prevalence of hookworm infection decreased
from 25.3% in 2002 to 8.2% in 2003 and the 5.9% in
2004 (Table 3). This is an average reduction of prevalence
of 76.7%. In children the rate of infection dropped from
19.3 to 7.2% in 2003 and remained low with 8.2% in
2004, while in the other age groups the decrease of preva-
lence continued also in 2004 (Fig. 3B). No difference in
hookworm reduction was observed in male and female
individuals. In the cohort of 226 individuals with full
annual data sets, the prevalence dropped from 2002 to
2004 from 34.5% to 17.3% and 14.2%, respectively. This
equals following two rounds of MDA within this time
course to a reduction of 59% (Fig. 4B). In 2003, 20 new
infections were observed and 59 individuals became
hookworm negative. In 2004, 25 new infections were
detected, while 32 persons turned negative. This corre-
sponds to an average rate of new infections of 13.5% and
an average clearance rate of about 80%. The mean egg
count before MDA was already relatively low, with about
65% of individuals with light infections of less than 2,000
eggs /g. In 2003 and 2004 the intensity of infection was
even lower with more than 90% having light infections.
The results from the formol/ether enrichment methods
were in principal confirmed by the data obtained from
Harada Mori culture, although in a few cases the hatching
test was more sensitive.
Trichuris trichiura
The crude prevalence of T. trichiura was almost stable from
2002 to 2004 with only a non-significant decrease from
9.4% to 8.7% and to 8.9%, respectively (Table 3). The
prevalence of infected children under the age ten years
increased only slightly from 9.6% in 2002 to 11.8% in
2003, but dropped to 7.6% in 2004 (Fig. 3C). A more pro-
nounced reduction of prevalence was observed in the
cohort of 226 individuals, who where examined in all
three years. In this group the prevalence was in 2002,
12.8% and a year later it was 10.2% and in 2004 it was
only 6.6%. This is a significant reduction over two years of
48.4%. In 2003, 18 individuals became negative for T.
trichiura eggs, while 12 new infections occurred. A year
later 22 individuals turned negative, while 2004, 14 new
infections occurred, of which 13 individuals were negative
at the surveys in 2002 and 2003 (Fig. 4C). The rate of new
infections in 2003 and 2004 was 6.1% and 7.0% respec-
tively. In this cohort 80% of the individuals who were
positive in 2002 became negative for T. trichiura in 2004,
but new infections occurred. The mean egg count before
MDA was already very low, with about 80% of individuals
having light infections of less than 2,000 eggs /g. In 2003
and 2004 the intensity of infection continued to be low
and almost all individuals had light infections.
Discussion
This study shows the effect of one selective treatment and
two rounds of MDA using DEC combined with alb on the
most prevalent helminths, B. timori, A. lumbricoides, hook-
worms and T. trichiura in a community on Alor island.
The results confirm and show for the first time at the com-
Table 3: Number of individuals examined for intestinal helminths from 2002 to 2004 grouped by infection status with A. lumbricoides, 
hookworms and Trichuris trichiura and the numbers of individuals who claimed to have been treated with DEC/albendazole in the 
previous year.
2002 No. (%) 2003 No. (%) 2004 No. (%)
Examined* Treated** Examined* Treated** Examined* Treated**
Ascaris
Negative 450 (67.8) 84 (18.7) 440 (77.9) 309 (70.2) 417 (72.4) 357 (85.6)
Positive 201 (32.2) 26 (12.9) 125 (22.1) 98 (78.4) 159 (27.6) 121 (76.1)
Hookworm
Negative 486 (74.7) 90 (18.5) 515 (91.8) 376 (73.0) 542 (94.1) 458 (84.5)
Positive 165 (25.3) 20 (12.1) 50 (8.2) 31 (62.0) 34 (5.9) 20 (58.8)
Trichuris
Negative 590 (90.6) 104 (17.6) 516 (91.3) 369 (71.5) 525 (91.1) 435 (82.9)
Positive 61 (9.4) 6 (6.6) 49 (8.7) 38 (77.6) 51 (8.9) 43 (84.3)
Total 651 (100) 110 (16.9) 565 (100) 407 (72.0) 576 (100) 478 (83.0)
*percentage of total examined, **percentage of negative or positive examinedFilaria Journal 2005, 4:5 http://www.filariajournal.com/content/4/1/5
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(A) Prevalence of A. lumbricoides positive individuals in Mainang village, Alor, Indonesia, from 2002 to 2004 by age Figure 3
(A) Prevalence of A. lumbricoides positive individuals in Mainang village, Alor, Indonesia, from 2002 to 2004 by age. The number 
of persons examined is noted on top of each column. DEC/albendazole MDA was performed after the surveys in 2002 and 
2003. (B) Prevalence of hookworm positive individuals in Mainang village, Alor, Indonesia, from 2002 to 2004 by age. (C) Prev-
alence of T. trichuria positive individuals in Mainang village, Alor, Indonesia, from 2002 to 2004 by age.
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(A) Number of people examined each year from 2002 to 2004 for Ascaris and the percentage (in brackets) of the infected (egg- positive) and non-infected (egg-negative) individuals for each group Figure 4
(A) Number of people examined each year from 2002 to 2004 for Ascaris and the percentage (in brackets) of the infected (egg-
positive) and non-infected (egg-negative) individuals for each group. The percentages on the arrow indicate the treatment com-
pliance. (B) Number of people examined each year from 2002 to 2004 for hookworm and the percentage of the infected and 
non-infected individuals for each group. The percentages on the arrow indicate the treatment compliance. (C) Number of peo-
ple examined each year from 2002 to 2004 for Trichuris and the percentage of the infected and non-infected individuals for each 
group. The percentages on the arrow indicate the treatment compliance.
2002 2003 2004 MDA MDA
127 [56.2]
82.9%
81.8%
94 [74.0]
74 [78.7]
20 [21.3]
97.3%
90.0%
33 [26.0]
21 [63.6]
12 [36.4]
95.2%
93.3%
99 [43.8]
92.6%
87.1%
68 [68.7]
50 [73.5]
18 [26.5]
96.0%
94.4%
31 [31.3]
21 [67.7]
10 [32.3]
100%
90.0%
A
148 [65.5]
86.7%
65.0%
128 [96.5]
112 [87.5]
16 [12.5]
93.8%
100%
20 [13.5]
18 [90.0]
2[ 1 0 . 0 ]
100%
100%
78 [34.5]
86.4%
84.2%
59 [75.6]
50 [84.7]
9[ 1 5 . 3 ]
96.0%
100%
19 [24.4]
14 [73.7]
5[ 2 6 . 3 ]
92.9%
80.0%
B
197 [87.2]
85.9%
66.7%
185 [93.9 ]
172 [93.0]
13 [7.0]
97.1%
92.3%
12 [6.1]
12 [100]
0
75.0%
29 [12.8]
100%
90.9%
18 [62.1]
17 [94.4]
1 [5.6]
88.2%
100%
11 [37.9]
10 [90.9]
1 [9.1]
100%
100%
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munity level, that the MDA approach as recommended by
the GPELF is highly effective at reducing the prevalence
and the intensity of infection of B. timori. Furthermore, a
positive impact on the prevalence, especially of hook-
worm infection, but also of A. lumbricoides and of T.
trichiura, was observed. The data support the hypothesis
that B. timori is an excellent candidate for elimination,
while the campaign will also have a large impact on the
reduction of intestinal helminths [15]. B. timori occurs
only east of the Wallace line in Indonesia and Timor-
Leste. This restricted distribution makes this species not
only a good candidate for local elimination, but B. timori
may also be a prime candidate for eradication of lym-
phatic filariae [15,21].
B. timori is closely related to B. malayi and tools and strat-
egies developed to support the elimination of B. malayi
infection may apply for both species [13-15,17,18]. It has
been shown that the combination of a single annual dose
of DEC combined with alb is very efficient in the control
of brugian filariasis and a higher efficacy of this regimen
has been suggested as compared to bancroftian filariasis
[6,13,14]. The successful control of B. timori on parts of
Flores island using multiple doses of DEC has been
reported already some decades ago [12]. However, this
strategy has caused many logistical problems and was
never extended to the remaining parts of Flores and other
islands. The present study proved the principle that a sin-
gle annual dose of DEC combined with alb is highly suit-
able to control and most probably to eliminate B. timori
infection. Before treatment, among a cohort of 145 indi-
viduals, 45 were mf-positive with a geometric mean mf
density of almost 150 mf/ml. Three years later, following
one selective treatment and two rounds of MDA in this
group only 3 individuals were found to be mf-positive,
who had mf densities of 1–2 mf/ml.
Our data show that a larger percentage of mf-positive indi-
viduals claimed not to have participated in MDA, com-
pared to the average compliance rate. It can be concluded
that a high compliance rate is necessary for reducing the
mf prevalence to levels under which transmission cannot
be sustained. In addition, a few individuals who received
no treatment still had high mf densities. If these individu-
als participate in the next rounds of MDA, side effects may
occur and affected individuals may spread their problems
in the community which eventually reduce compliance.
However, extensive health information campaigns can
help to ensure high compliance rates [19].
On the community level not much data exists about the
control of brugian filariasis by annual MDA using DEC
combined with alb. For the control of W. bancrofti infec-
tion in Asia a number of extensive field studies were pub-
lished using annual MDA with DEC alone or in
combination with alb. Results from Papua New Guinea
indicate promising prospects for elimination [22,23]. In
India, after six rounds of a single dose treatment with DEC
the prevalence of microfilaraemics was reduced by 86%
and the mf density by 91% [7]. Computer models predict
that in this area a further decline of mf prevalence will
occur even after the cessation of MDA [24]. In this study
(B.timori), similar reductions of prevalence and mf den-
sity were observed after only one selective treatment and
two rounds of MDA. It is possible that models would also
predict a further decline of mf prevalence for our study,
but epidemiological parameters differ largely between W.
bancrofti infections in Pondicherry (India) and B. timori
infections on Alor island and further studies on the
dynamics of B. timori control are needed. In addition, it
has been discussed for W. bancrofti in the pacific area that
MDA should be accompanied by local vector control [25].
Our results showed that MDA using a combination of
DEC and alb also has an impact on the reduction of intes-
tinal nematode infections. In the highland village exam-
ined the original prevalence and intensity of infections
with A. lumbricoides, hookworms and T. trichiura was rela-
tively low. This is in agreement with previous surveys on
Alor and on other islands of volcanic origin in east Nusa
Tenggara Timur [26,27]. Although, both hookworm spe-
cies occur in eastern Indonesia, data from Flores indicate
that Necator americanus, may be the prominent species
[27].
The strongest reduction of prevalence following two
rounds of MDA among the intestinal helminths was
observed in hookworm infections, in both, the cross-sec-
tional group of an average of 600 individuals and a cohort
of 226 individuals. Although a large number of re-infec-
tions occurred, the crude prevalence dropped from 25.3%
to 5.9% and in the cohort from 34.5% to 14.2%, ten
months after the second round of MDA. This equals a
reduction of 76.7% and 58.8%, respectively. The hook-
worm prevalence is usually reduced by about 80% shortly
after treatment with alb [28,29]. Although DEC alone may
reduce the output of hookworm eggs, it is assumed that it
has no influence on its prevalence [30]. In our study we
observed a large number of hookworm re- or new infec-
tions. In 13.5% (2003) and 14.0% (2004) of the cohort
new infections were observed. From Java, an even higher
re-infection rate with N. americanus of about 50% one
year after anthelminthic treatment was reported [31].
Despite of the occurrence of re-and new infections, the
drop in hookworm prevalence can be explained by the rel-
atively short survival time of hookworm larvae in the
environment as compared to the mean survival time of
eggs of A. lumbricoides and of T. trichiura.Filaria Journal 2005, 4:5 http://www.filariajournal.com/content/4/1/5
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Following the first round of MDA the crude prevalence of
A. lumbricoides dropped from 32.2% to 22.1%, but after
the second round it was 27.6%. More consistently were
the results in the cohort. Before MDA the prevalence was
43.3%, following the first round it was 28.3% and follow-
ing the second round it was 26.5%. Albendazole is very
effective against A. lumbricoides and median cure rates are
over 95% [28,29,32]. DEC alone has a minor therapeutic
effect on Ascaris [10,33]. Although some treated individu-
als may expel adult worms after DEC, the overall preva-
lence of infection may be not affected [30]. These
observations are confirmed by other studies, which show
that DEC alone has no significant impact on A. lumbri-
coides, but the combination of DEC with alb has relevant
cure and egg reduction rates [34]. As in other intestinal
helminths, re- and new infections occur regularly, and the
time point of re-examination is critical. In our cohort we
observed an annual rate of new infections of 25%. Chil-
dren have an especially high risk for re- or new-infections
and show a lower decrease in worm burden compared to
adults [35]. In another study it was observed that eight
months after treatment 55% of children were re-infected
[36]. Re-infection with A. lumbricoides may return six
months after treatment to almost 90% of the pre-treat-
ment prevalence and worm density may drop to about
75% [35].
The crude prevalence of T. trichiura in the community
before and after MDA was almost identical, ranging
between 9.4% and 8.7%. However, following two rounds
of MDA the prevalence dropped in the cohort from 12.8%
to 6.6%. Although re- and new infections occurred, it is
important to note that in 2004 most new infections were
observed in those individuals which were negative for T.
trichiura for the previous two years. Trichuris trichiura is
known to be only poorly sensitive to albendazole and the
reported reduction rates for alb range between 38% and
47.7% [28,29,32]. From Sri Lanka a cure rate of T. trichiura
of 43.6% and an egg reduction rate of 70.3% was reported
[37]. The combination of DEC with alb showed different
results, ranging from no significant impact on the preva-
lence but with significant egg reduction of 79.4% one
week after treatment, to a cure rate of 81.6% and an egg
reduction of 84% [10,34]. The study from Sri Lanka
reported that this drug combination has a cure rate of
30% and an egg reduction rate of 70% [36].
For areas endemic for W. bancrofti there are an increasing
number of studies which show the positive effect of
filariasis control using MDA with DEC combined with alb
on the reduction of intestinal helminths [8-11,38]. The
results of the present study can extend this observation to
areas endemic for Brugia infections. Although it is unlikely
that MDA as used for filariasis elimination will eliminate
intestinal helminths from most areas, a reduction may be
achieved to levels which may cause no significant morbid-
ity. Other intervention strategies, such as for example the
development of a hookworm vaccine [39], may take
advantage of reduced prevalences in order to achieve a
long-lasting elimination of intestinal helminths, as it has
been accomplished in most industrialised countries. In
areas with filariasis control by the MDA using DEC com-
bined with alb, separate de-worming campaigns for
school-age children may become superfluous. This could
set available resources free which can then be used to sup-
port MDA. Co-ordination is needed within the local
health administration to use the limited funds more effi-
ciently. The present study showed that MDA using DEC
combined with alb is effective to control B. timori and that
this has also impact on the reduction of geohelminths.
Conclusion
Annual MDA using DEC in combination with alb is
highly effective in the control of B. timori infection and
has a positive impact on the reduction of intestinal
helminths. Given a high compliance rate the strategy can
lead to elimination of B. timori on Alor and on other
islands in Indonesia.
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